Miltenyi Biotec acquires biosensor company lino Biotech

Wednesday, March 15, 2023 @ 12:00 am

lino Biotech, a leading biosensor company and the world's only provider of Focal Molography, announced today it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023.

Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy manufacturing, and testing for off-target responses in living cells to support drug discovery.

Headquartered in Bergisch Gladbach, Miltenyi Biotec has been a global provider of products and services for biomedical research and cellular therapy for more than 30 years.

Under the terms of the transaction, Miltenyi Biotec will acquire 100% of the shares from the investors including Roche Venture Fund and High-Tech Gründerfonds. The specific terms of the transaction were not disclosed.

"lino´s innovative biosensor platform and Miltenyi's cell and gene therapy approaches offer exciting synergies to lower the cost and establish a new standard for potency assays," said Dr. Mirko Stange, CEO of lino Biotech.

lino's headquarters in Zurich will be further expanded for research, chip, and application development.

You May Also Be Interested In

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Nouscom: Patient enrollment of study for metastatic colorectal cancer completed

Primary efficacy endpoint readout expected in mid-2025 Phase 1b studies in dMMR/MSI GI tumors showed that NOUS-209 with pembrolizumab was well-tolerated, generating potent and broad immune responses and durable tumor shrinkage NOUS-209 is being evaluated in multiple clinical studies targeting MSI cancers, from early-stage cancer interception through to metastatic disease
November 19, 2024

InSphero awarded major EU grant for diversity in 3D in vitro testing

InSphero, the global leader in scalable and reliable 3D in vitro cell culture solutions for drug discovery, takes a leading role in the recently awarded Chips JU European UNLOOC Project to advance its technology platform and address diversity in drug efficacy and safety testing.
November 18, 2024

Ymmunobio honored with 3rd place at the Prix Galien USA Awards

Ymmunobio is proud to announce its recent recognition at the prestigious Prix Galien USA Awards, where the company achieved a 3rd-place honor. The Prix Galien Award acknowledges Ymmunobio’s dedication to advancing science and healthcare.
November 15, 2024

Pharvaris: 3rd quarter 2024 financial results and business updates

Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congresses Intend to engage in clinical development of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH) Initiation of CHAPTER-3 global pivotal Phase 3 clinical study of deucrictibant for the
November 13, 2024

Aurealis Therapeutics: CHF 8M for chronic wounds studies and oncology program

Funds will be used to complete Phase 2 RCTs with AUP-16 for Chronic Wounds, and accelerate the development of AUP-55 for ovarian, peritoneal and bladder cancer.
November 13, 2024